Toll-like receptor 9 agonists as cancer therapeutics

Bibliography

• Janeway CA Jr. How the immune system recognizes invaders. Sci Am 1993;269(3):72-9
   PubMed Web of Science ®Google Scholar
• Medzhitov R, Janeway CA Jr. Innate immunity: impact on the adaptive immune response. Curr Opin Immunol 1997;9(1):4-9
   PubMed Web of Science ®Google Scholar
• Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997;388(6640):394-7
   PubMed Web of Science ®Google Scholar
• Akira S, Hemmi H. Recognition of pathogen-associated molecular patterns by TLR family. Immunol Lett 2003;85(2):85-95
   PubMed Web of Science ®Google Scholar
• O'Neill LA, Bryant CE, Doyle SL. Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer. Pharmacol Rev 2009;61(2):177-97
   PubMed Web of Science ®Google Scholar
• Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004;5(10):987-95
   PubMed Web of Science ®Google Scholar
• Kawai T, Akira S. Signaling to NF-kappaB by Toll-like receptors. Trends Mol Med 2007;13(11):460-9
   PubMed Web of Science ®Google Scholar
• Miyake K. Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors. Semin Immunol 2007;19(1):3-10
   PubMed Web of Science ®Google Scholar
• Hoshino K, Takeuchi O, Kawai T, Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol 1999;162(7):3749-52
   PubMed Web of Science ®Google Scholar
• Hayashi F, Smith KD, Ozinsky A, The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 2001;410(6832):1099-103
   PubMed Web of Science ®Google Scholar
• Takeuchi O, Hoshino K, Kawai T, Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity 1999;11(4):443-51
   PubMed Web of Science ®Google Scholar
• Liu L, Botos I, Wang Y, Structural basis of toll-like receptor 3 signaling with double-stranded RNA. Science 2008;320(5874):379-81
   PubMed Web of Science ®Google Scholar
• Alexopoulou L, Holt AC, Medzhitov R, Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001;413(6857):732-8
   PubMed Web of Science ®Google Scholar
• Lee J, Chuang TH, Redecke V, Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of Toll-like receptor 7. Proc Natl Acad Sci USA 2003;100(11):6646-51
   PubMed Web of Science ®Google Scholar
• Bauer S, Kirschning CJ, Hacker H, Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci USA 2001;98(16):9237-42
   PubMed Web of Science ®Google Scholar
• Ahmad-Nejad P, Hacker H, Rutz M, Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. Eur J Immunol 2002;32(7):1958-68
   PubMed Web of Science ®Google Scholar
• Hemmi H, Takeuchi O, Kawai T, A Toll-like receptor recognizes bacterial DNA. Nature 2000;408(6813):740-5
   PubMed Web of Science ®Google Scholar
• Haas T, Metzger J, Schmitz F, The DNA sugar backbone 2′ deoxyribose determines toll-like receptor 9 activation. Immunity 2008;28(3):315-23
   PubMed Web of Science ®Google Scholar
• Wagner H. The sweetness of the DNA backbone drives Toll-like receptor 9. Curr Opin Immunol 2008;20(4):396-400
   PubMed Web of Science ®Google Scholar
• Leifer CA, Kennedy MN, Mazzoni A, TLR9 is localized in the endoplasmic reticulum prior to stimulation. J Immunol 2004;173(2):1179-83
   PubMed Web of Science ®Google Scholar
• Zarember KA, Godowski PJ. Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J Immunol 2002;168(2):554-61
   PubMed Web of Science ®Google Scholar
• Agrawal S, Kandimalla ER. Synthetic agonists of Toll-like receptors 7, 8 and 9. Biochem Soc Trans 2007;35(Pt 6):1461-7
   PubMedGoogle Scholar
• Saikh KU, Kissner TL, Sultana A, Human monocytes infected with Yersinia pestis express cell surface TLR9 and differentiate into dendritic cells. J Immunol 2004;173(12):7426-34
   PubMed Web of Science ®Google Scholar
• Hayashi F, Means TK, Luster AD. Toll-like receptors stimulate human neutrophil function. Blood 2003;102(7):2660-9
   PubMed Web of Science ®Google Scholar
• Gelman AE, LaRosa DF, Zhang J, The adaptor molecule MyD88 activates PI-3 kinase signaling in CD4+ T cells and enables CpG oligodeoxynucleotide-mediated costimulation. Immunity 2006;25(5):783-93
   PubMed Web of Science ®Google Scholar
• Urry Z, Xystrakis E, Richards DF, Ligation of TLR9 induced on human IL-10-secreting tregs by 1alpha,25-dihydroxyvitamin D3 abrogates regulatory function. J Clin Invest 2009;119(2):387-98
   PubMed Web of Science ®Google Scholar
• Platz J, Beisswenger C, Dalpke A, Microbial DNA induces a host defense reaction of human respiratory epithelial cells. J Immunol 2004;173(2):1219-23
   PubMed Web of Science ®Google Scholar
• Pedersen G, Andresen L, Matthiessen MW, Expression of Toll-like receptor 9 and response to bacterial CpG oligodeoxynucleotides in human intestinal epithelium. Clin Exp Immunol 2005;141(2):298-306
   PubMed Web of Science ®Google Scholar
• Andersen JM, Al-Khairy D, Ingalls RR. Innate immunity at the mucosal surface: role of toll-like receptor 3 and toll-like receptor 9 in cervical epithelial cell responses to microbial pathogens. Biol Reprod 2006;74(5):824-31
   PubMed Web of Science ®Google Scholar
• Lebre MC, van der Aar AM, van Baarsen L, Human keratinocytes express functional Toll-like receptor 3, 4, 5, and 9. J Invest Dermatol 2007;127(2):331-41
   PubMed Web of Science ®Google Scholar
• Yu L, Chen S. Toll-like receptors expressed in tumor cells: targets for therapy. Cancer Immunol Immunother 2008;57(9):1271-8
   PubMed Web of Science ®Google Scholar
• Chiron D, Bekeredjian-Ding I, Pellat-Deceunynck C, Toll-like receptors: lessons to learn from normal and malignant human B cells. Blood 2008;112(6):2205-13
   PubMed Web of Science ®Google Scholar
• Assaf A, Esteves H, Curnow SJ, A threshold level of TLR9 mRNA predicts cellular responsiveness to CpG-ODN in haematological and non-haematological tumour cell lines. Cell Immunol 2009;259(1):90-9
   PubMed Web of Science ®Google Scholar
• Jego G, Bataille R, Geffroy-Luseau A, Pathogen-associated molecular patterns are growth and survival factors for human myeloma cells through Toll-like receptors. Leukemia 2006;20(6):1130-7
   PubMed Web of Science ®Google Scholar
• Droemann D, Albrecht D, Gerdes J, Human lung cancer cells express functionally active Toll-like receptor 9. Respir Res 2005;6:1
   PubMed Web of Science ®Google Scholar
• Merrell MA, Ilvesaro JM, Lehtonen N, Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity. Mol Cancer Res 2006;4(7):437-47
   PubMed Web of Science ®Google Scholar
• Huang B, Zhao J, Unkeless JC, TLR signaling by tumor and immune cells: a double-edged sword. Oncogene 2008;27(2):218-24
   PubMed Web of Science ®Google Scholar
• Jahrsdorfer B, Muhlenhoff L, Blackwell SE, B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides. Clin Cancer Res 2005;11(4):1490-9
   PubMed Web of Science ®Google Scholar
• Kim YM, Brinkmann MM, Paquet ME, UNC93B1 delivers nucleotide-sensing toll-like receptors to endolysosomes. Nature 2008;452(7184):234-8
   PubMed Web of Science ®Google Scholar
• Latz E, Schoenemeyer A, Visintin A, TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol 2004;5(2):190-8
   PubMed Web of Science ®Google Scholar
• Hacker H. Signal transduction pathways activated by CpG-DNA. Curr Top Microbiol Immunol 2000;247:77-92
   PubMed Web of Science ®Google Scholar
• Hacker H, Vabulas RM, Takeuchi O, Immune cell activation by bacterial CpG-DNA through myeloid differentiation marker 88 and tumor necrosis factor receptor-associated factor (TRAF)6. J Exp Med 2000;192(4):595-600
   PubMed Web of Science ®Google Scholar
• Latz E, Verma A, Visintin A, Ligand-induced conformational changes allosterically activate Toll-like receptor 9. Nat Immunol 2007;8(7):772-9
   PubMed Web of Science ®Google Scholar
• Ishii KJ, Akira S. Innate immune recognition of, and regulation by, DNA. Trends Immunol 2006;27(11):525-32
   PubMed Web of Science ®Google Scholar
• Krieg AM, Yi AK, Matson S, CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995;374(6522):546-9
   PubMed Web of Science ®Google Scholar
• Krug A, Rothenfusser S, Hornung V, Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur J Immunol 2001;31(7):2154-63
   PubMed Web of Science ®Google Scholar
• Kemp TJ, Elzey BD, Griffith TS. Plasmacytoid dendritic cell-derived IFN-alpha induces TNF-related apoptosis-inducing ligand/Apo-2L-mediated antitumor activity by human monocytes following CpG oligodeoxynucleotide stimulation. J Immunol 2003;171(1):212-18
   PubMed Web of Science ®Google Scholar
• Kemp TJ, Moore JM, Griffith TS. Human B cells express functional TRAIL/Apo-2 ligand after CpG-containing oligodeoxynucleotide stimulation. J Immunol 2004;173(2):892-9
   PubMed Web of Science ®Google Scholar
• Bekeredjian-Ding I, Jego G. Toll-like receptors–sentries in the B-cell response. Immunology 2009;128(3):311-23
   PubMed Web of Science ®Google Scholar
• Bernasconi NL, Onai N, Lanzavecchia A. A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. Blood 2003;101(11):4500-4
   PubMed Web of Science ®Google Scholar
• Bernasconi NL, Traggiai E, Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 2002;298(5601):2199-202
   PubMed Web of Science ®Google Scholar
• Jung J, Yi AK, Zhang X, Distinct response of human B cell subpopulations in recognition of an innate immune signal, CpG DNA. J Immunol 2002;169(5):2368-73
   PubMed Web of Science ®Google Scholar
• Eckl-Dorna J, Batista FD. BCR-mediated uptake of antigenlinked to TLR9 ligand stimulates B-cell proliferation and antigen-specific plasma cell formation. Blood 2009;113(17):3969-77
   PubMed Web of Science ®Google Scholar
• Hanten JA, Vasilakos JP, Riter CL, Comparison of human B cell activation by TLR7 and TLR9 agonists. BMC Immunol 2008;9:39
   PubMed Web of Science ®Google Scholar
• Gantner F, Hermann P, Nakashima K, CD40-dependent and -independent activation of human tonsil B cells by CpG oligodeoxynucleotides. Eur J Immunol 2003;33(6):1576-85
   PubMed Web of Science ®Google Scholar
• Wagner M, Poeck H, Jahrsdoerfer B, IL-12p70-dependent Th1 induction by human B cells requires combined activation with CD40 ligand and CpG DNA. J Immunol 2004;172(2):954-63
   PubMed Web of Science ®Google Scholar
• Agrawal S, Gupta S. TLR1/2, TLR7, and TLR9 signals directly activate human peripheral blood naive and memory B Cell subsets to produce cytokines, chemokines, and hematopoietic growth factors. J Clin Immunol 2010;2010:7
   Google Scholar
• Carpenter EL, Mick R, Ruter J, Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation. J Transl Med 2009;7:93
   PubMed Web of Science ®Google Scholar
• Verthelyi D, Ishii KJ, Gursel M, Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs. J Immunol 2001;166(4):2372-7
   PubMed Web of Science ®Google Scholar
• Vollmer J, Weeratna R, Payette P, Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol 2004;34(1):251-62
   PubMed Web of Science ®Google Scholar
• Sester DP, Naik S, Beasley SJ, Phosphorothioate backbone modification modulates macrophage activation by CpG DNA. J Immunol 2000;165(8):4165-73
   PubMed Web of Science ®Google Scholar
• Hartmann G, Krieg AM. Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J Immunol 2000;164(2):944-53
   PubMed Web of Science ®Google Scholar
• Hartmann G, Weeratna RD, Ballas ZK, Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J Immunol 2000;164(3):1617-24
   PubMed Web of Science ®Google Scholar
• Yu D, Kandimalla ER, Zhao Q, Immunostimulatory activity of CpG oligonucleotides containing non-ionic methylphosphonate linkages. Bioorg Med Chem 2001;9(11):2803-8
   PubMed Web of Science ®Google Scholar
• Yu D, Kandimalla ER, Zhao Q, Modulation of immunostimulatory activity of CpG oligonucleotides by site-specific deletion of nucleobases. Bioorg Med Chem Lett 2001;11(17):2263-7
   PubMed Web of Science ®Google Scholar
• Sheehan JP, Lan HC. Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex. Blood 1998;92(5):1617-25
   PubMed Web of Science ®Google Scholar
• Guvakova MA, Yakubov LA, Vlodavsky I, Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix. J Biol Chem 1995;270(6):2620-7
   PubMed Web of Science ®Google Scholar
• Brown DA, Kang SH, Gryaznov SM, Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding. J Biol Chem 1994;269(43):26801-5
   PubMed Web of Science ®Google Scholar
• Henry SP, Beattie G, Yeh G, Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide. Int Immunopharmacol 2002;2(12):1657-66
   PubMed Web of Science ®Google Scholar
• Heikenwalder M, Polymenidou M, Junt T, Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat Med 2004;10(2):187-92
   PubMed Web of Science ®Google Scholar
• Chiron D, Pellat-Deceunynck C, Maillasson M, Phosphorothioate-modified TLR9 ligands protect cancer cells against TRAIL-induced apoptosis. J Immunol 2009;183(7):4371-7
   PubMed Web of Science ®Google Scholar
• Struthers M, Bett AJ, Wisniewski T, Synthesis and immunological activities of novel agonists of toll-like receptor 9. Cell Immunol 2010;263(1):105-13
   PubMed Web of Science ®Google Scholar
• Kandimalla ER, Bhagat L, Yu D, Conjugation of ligands at the 5′-end of CpG DNA affects immunostimulatory activity. Bioconjug Chem 2002;13(5):966-74
   PubMed Web of Science ®Google Scholar
• Yu D, Kandimalla ER, Bhagat L, ‘Immunomers’–novel 3′-3′-linked CpG oligodeoxyribonucleotides as potent immunomodulatory agents. Nucleic Acids Res 2002;30(20):4460-9
   PubMed Web of Science ®Google Scholar
• Agrawal S, Kandimalla ER. Modulation of Toll-like receptor 9 responses through synthetic immunostimulatory motifs of DNA. Ann N Y Acad Sci 2003;1002:30-42
   PubMed Web of Science ®Google Scholar
• Schmidt M, Cristobal J, Hagner N, Potent phosphorodiester-based DNA immunomodulators (dSLIM) exhibit enhanced safety compared to phosphorothioate-based oligonucleotides [abstract #3915]. Blood 2005;106(Suppl 1):59b
   PubMedGoogle Scholar
• Schmidt M, Anton K, Nordhaus C, Cytokine and Ig-production by CG-containing sequences with phosphorodiester backbone and dumbbell-shape. Allergy 2006;61(1):56-63
   PubMed Web of Science ®Google Scholar
• Schmidt M, Cristobal J, Sander A, dSLIM immunomodulators induce anti-tumor responses both in vitro and in vivo [abstract #1727]. Blood 2006;108(Suppl 1):490a
   Google Scholar
• Schmidt M, Brzezicha B, Chen Y, dSLIM immunomodulators reduce tumor growth in various animal tumor models [abstract #935]. Mol Ther 2008;16(Suppl 1):389
   Google Scholar
• Krieg AM. The toll of too much TLR7. Immunity 2007;27(5):695-7
   PubMed Web of Science ®Google Scholar
• Milas L, Mason KA, Ariga H, CpG oligodeoxynucleotide enhances tumor response to radiation. Cancer Res 2004;64(15):5074-7
   PubMed Web of Science ®Google Scholar
• Balsari A, Tortoreto M, Besusso D, Combination of a CpG-oligodeoxynucleotide and a topoisomerase I inhibitor in the therapy of human tumour xenografts. Eur J Cancer 2004;40(8):1275-81
   PubMed Web of Science ®Google Scholar
• Vicari AP, Luu R, Zhang N, Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse. Cancer Immunol Immunother 2009;58(4):615-28
   PubMed Web of Science ®Google Scholar
• Weigel BJ, Rodeberg DA, Krieg AM, CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma. Clin Cancer Res 2003;9(8):3105-14
   PubMed Web of Science ®Google Scholar
• Wang XS, Sheng Z, Ruan YB, CpG oligodeoxynucleotides inhibit tumor growth and reverse the immunosuppression caused by the therapy with 5-fluorouracil in murine hepatoma. World J Gastroenterol 2005;11(8):1220-4
   PubMed Web of Science ®Google Scholar
• Warren TL, Dahle CE, Weiner GJ. CpG oligodeoxynucleotides enhance monoclonal antibody therapy of a murine lymphoma. Clin Lymphoma 2000;1(1):57-61
   PubMedGoogle Scholar
• Wooldridge JE, Ballas Z, Krieg AM, Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. Blood 1997;89(8):2994-8
   PubMed Web of Science ®Google Scholar
• Kochling J, Prada J, Bahrami M, Anti-tumor effect of DNA-based vaccination and dSLIM immunomodulatory molecules in mice with Ph+ acute lymphoblastic leukaemia. Vaccine 2008;26(36):4669-75
   PubMed Web of Science ®Google Scholar
• Krieg AM. Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides. Curr Oncol Rep 2004;6(2):88-95
   PubMedGoogle Scholar
• Weiner GJ, Liu HM, Wooldridge JE, Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci USA 1997;94(20):10833-7
   PubMed Web of Science ®Google Scholar
• Nierkens S, den Brok MH, Roelofsen T, Route of administration of the TLR9 agonist CpG critically determines the efficacy of cancer immunotherapy in mice. PLoS One 2009;4(12):e8368
   PubMedGoogle Scholar
• Beyer M, Schultze JL. Regulatory T cells: major players in the tumor microenvironment. Curr Pharm Des 2009;15(16):1879-92
   PubMed Web of Science ®Google Scholar
• Hall JA, Bouladoux N, Sun CM, Commensal DNA limits regulatory T cell conversion and is a natural adjuvant of intestinal immune responses. Immunity 2008;29(4):637-49
   PubMed Web of Science ®Google Scholar
• Moseman EA, Liang X, Dawson AJ, Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+CD25+ regulatory T cells. J Immunol 2004;173(7):4433-42
   PubMed Web of Science ®Google Scholar
• Ouabed A, Hubert FX, Chabannes D, Differential control of T regulatory cell proliferation and suppressive activity by mature plasmacytoid versus conventional spleen dendritic cells. J Immunol 2008;180(9):5862-70
   PubMed Web of Science ®Google Scholar
• Ciorba MA, Bettonville EE, McDonald KG, Induction of IDO-1 by immunostimulatory DNA limits severity of experimental colitis. J Immunol 2010;184(7):3907-16
   PubMed Web of Science ®Google Scholar
• Johnson BA III, Kahler DJ, Baban B, B-lymphoid cells with attributes of dendritic cells regulate T cells via indoleamine 2,3-dioxygenase. Proc 2010;107(23):10644-8
   Google Scholar
• Zhang X, Munegowda MA, Yuan J, Optimal TLR9 signal converts tolerogenic CD4-8- DCs into immunogenic ones capable of stimulating antitumor immunity via activating CD4+ Th1/Th17 and NK cell responses. J Leukoc Biol 2010;88(2):393-403
   PubMed Web of Science ®Google Scholar
• Damiano V, Caputo R, Bianco R, Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors. Clin Cancer Res 2006;12(2):577-83
   PubMed Web of Science ®Google Scholar
• Damiano V, Caputo R, Garofalo S, TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts. Proc Natl Acad Sci USA 2007;104(30):12468-73
   PubMed Web of Science ®Google Scholar
• Damiano V, Garofalo S, Rosa R, A novel toll-like receptor 9 agonist cooperates with trastuzumab in trastuzumab-resistant breast tumors through multiple mechanisms of action. Clin Cancer Res 2009;15(22):6921-30
   PubMed Web of Science ®Google Scholar
• Ichikawa HT, Williams LP, Segal BM. Activation of APCs through CD40 or Toll-like receptor 9 overcomes tolerance and precipitates autoimmune disease. J Immunol 2002;169(5):2781-7
   PubMed Web of Science ®Google Scholar
• Ronaghy A, Prakken BJ, Takabayashi K, Immunostimulatory DNA sequences influence the course of adjuvant arthritis. J Immunol 2002;168(1):51-6
   PubMed Web of Science ®Google Scholar
• Speiser DE, Lienard D, Rufer N, Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 2005;115(3):739-46
   PubMed Web of Science ®Google Scholar
• van Ojik HH. Phase I/II study with CpG 7909 as adjuvant to vaccination with MAGA-3 protein in patients with MAGE-3 positive tumors 13:157 [abstract]. Ann Oncol 2002;13(Suppl):157
   PubMedGoogle Scholar
• Fourcade J, Kudela P, Andrade Filho PA, Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients. J Immunother 2008;31(8):781-91
   PubMed Web of Science ®Google Scholar
• van den Eertwegh AJM, Lensen RJ, Scheper RJ, Autologous tumor cell vaccination with PF-3512676 (CPG 7909) and GM-CSF followed by subcutaneous PF-3512676 and IFN-alpha for patients with metastatic renal cell carcinoma [abstract 24]. ASCO Meeting; 2006. p. 2530
   Google Scholar
• Thompson JA, Kuzel T, Drucker BJ, Safety and efficacy of PF-3512676 for the treatment of stage IV renal cell carcinoma: an open-label, multicenter phase I/II study. Clin Genitourin Cancer 2009;7(3):E58-65
   PubMed Web of Science ®Google Scholar
• Molenkamp BG, Sluijter BJ, van Leeuwen PA, Local administration of PF-3512676 CpG-B instigates tumor-specific CD8+ T-cell reactivity in melanoma patients. Clin Cancer Res 2008;14(14):4532-42
   PubMed Web of Science ®Google Scholar
• Molenkamp BG, van Leeuwen PA, Meijer S, Intradermal CpG-B activates both plasmacytoid and myeloid dendritic cells in the sentinel lymph node of melanoma patients. Clin Cancer Res 2007;13(10):2961-9
   PubMed Web of Science ®Google Scholar
• Hofmann MA, Kors C, Audring H, Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma. J Immunother 2008;31(5):520-7
   PubMed Web of Science ®Google Scholar
• Pashenkov M, Goess G, Wagner C, Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J Clin Oncol 2006;24(36):5716-24
   PubMed Web of Science ®Google Scholar
• Brody JD, Ai WZ, Czerwinski DK, In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a Phase I/II study. J Clin Oncol 2010;28(28):4295-6
   PubMedGoogle Scholar
• Leonard JP, Link BK, Emmanouilides C, Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma. Clin Cancer Res 2007;13(20):6168-74
   PubMed Web of Science ®Google Scholar
• Manegold C, Gravenor D, Woytowitz D, Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26(24):3979-86
   PubMed Web of Science ®Google Scholar
• Weber JS, Zarour H, Redman B, Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma. Cancer 2009;115(17):3944-54
   PubMed Web of Science ®Google Scholar
• Carpentier A, Laigle-Donadey F, Zohar S, Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma. Neuro Oncol 2006;8(1):60-6
   PubMed Web of Science ®Google Scholar
• Carpentier A, Metellus P, Ursu R, Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study. Neuro Oncol 2010;12(4):401-8
   PubMed Web of Science ®Google Scholar
• Kuzel T, Dutcher J, Ebbinghaus S, A phase 2 multicenter, randomized, open-label study of two dose levels of IMO-2055 in patients with metastatic or recurrent renal cell carcinoma. Eighth International Kidney Cancer Symposium; Chicago; 2009
   Google Scholar
• Smith D, Conkling P, Richards D, Phase I study of the toll like receptor 9 agonist IMO-2055 combined with erlotinib and bevacizumab in patients with advanced or metastatic non-small cell lung cancer [abstract number 9148]. 15th Congress of the European CanCer Organisation (ECCO) and 34th Congress of the European Society for Medical Oncology (ESMO) in Berlin; Germany, 2009
   Google Scholar
• Weihrauch MR, Ansen S, Jurkiewicz E, Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer. Clin Cancer Res 2005;11(16):5993-6001
   PubMed Web of Science ®Google Scholar
• Scheulen ME, Schmidt M, von Bergwelt-Baildon M, Safety results of a Phase 1 clinical study for treatment of patients with advanced solid tumors with the TLR9 agonist MGN1703 [abstract #887]. Mol Ther 2010;18(Suppl 1):342
   Google Scholar
• Weihrauch MR, Schmidt M, Richly H, Treatment with the TLR9 agonist MGN1703 in patients with metastatic solid tumors – Efficacy Results of a Phase 1 Clinical Study [abstract #664]. Mol Ther 2010;18(Suppl 1):259
   Google Scholar
• Tokunaga T, Yamamoto T, Yamamoto S. How BCG led to the discovery of immunostimulatory DNA. Jpn J Infect Dis 1999;52(1):1-11
   PubMed Web of Science ®Google Scholar
• Goldstein MJ, Varghese B, Brody JD, A CpG-loaded tumor cell vaccine induces anti-tumor CD4+ T cells that are effective in adoptive therapy for large and established tumors. Blood 2010;2010:27
   Google Scholar
• Conforti A, Cipriani B, Peruzzi D, A TLR9 agonist enhances therapeutic effects of telomerase genetic vaccine. Vaccine 2010;28(20):3522-30
   PubMed Web of Science ®Google Scholar
• Haining WN, Davies J, Kanzler H, CpG oligodeoxynucleotides alter lymphocyte and dendritic cell trafficking in humans. Clin Cancer Res 2008;14(17):5626-34
   PubMed Web of Science ®Google Scholar
• Carpenter EL, Mick R, Rech AJ, Collapse of the CD27+ B-cell compartment associated with systemic plasmacytosis in patients with advanced melanoma and other cancers. Clin Cancer Res 2009;15(13):4277-87
   PubMed Web of Science ®Google Scholar